{"id":308,"date":"2020-02-16T10:38:34","date_gmt":"2020-02-16T05:08:34","guid":{"rendered":"https:\/\/medicineplexus.com\/?p=308"},"modified":"2020-02-16T10:38:34","modified_gmt":"2020-02-16T05:08:34","slug":"recent-advances-in-treatment-of-diabetes-mellitus","status":"publish","type":"post","link":"https:\/\/medicineplexus.com\/recent-advances-in-treatment-of-diabetes-mellitus\/","title":{"rendered":"Recent advances in Treatment of Diabetes Mellitus"},"content":{"rendered":"\n
Recent advances Diabetes Mellitus<\/em><\/strong><\/p>\n\n\n\n Why need newer drugs?<\/em><\/strong><\/em><\/strong><\/p>\n\n\n\n Limitations of existing drugs:<\/em><\/strong><\/p>\n\n\n\n Insulins: Repeated injections, Lipodystrophy, insulin resistance, cannot mimic the physiological nature of insulin release<\/em><\/p>\n\n\n\n OHAs: Adverse effect profile-unacceptable: weight gain; abdominal distention and flatulence with acarbose<\/em><\/p>\n\n\n\n Basic pathology is left unaltered, no strategy available to protect beta cells<\/em><\/p>\n\n\n\n Type I DM<\/strong><\/p>\n\n\n\n Degludec is injected subcutaneously:<\/p>\n\n\n\n these two characteristics contribute to the prolonged effect of Degludec (>24 h at steady state).<\/p>\n\n\n\n